Gornitzky represented the underwriters, led by Oppenheimer & Co., in the USD 57.5 million follow-on offering of Intec Pharma Ltd. on the NASDAQ Capital Market. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology.
Oppenheimer & Co. Inc. acted as sole book-running manager for the offering. Roth Capital Partners acted as lead manager, and Maxim Group LLC acted as co-manager for the offering.
The underwriters were represented by Chaim Friedland (Partner), Ari Fried (Partner), Danielle Skald (Associate) and Nir Knoll (Associate).
